Monomeric C-reactive protein is prothrombotic and dissociates from circulating pentameric C-reactive protein on adhered activated platelets under flow

Cardiovascular Research

Volumn 92, Issue 2, 2011, Pages 328-337

  Molins, Blanca ^a,b   Pea, Esther ^a,b   De La Torre, Raquel ^a,b   Badimon, Lina ^a,b,c  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

C reactive protein; Dissociation; Platelets; Thrombosis

Indexed keywords

C REACTIVE PROTEIN; CD36 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; SYNAPTOPHYSIN; VASODILATOR STIMULATED PHOSPHOPROTEIN;

ARTICLE; BLOOD CLOTTING; CONFOCAL MICROSCOPY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IMMUNOFLUORESCENCE; NORMAL HUMAN; PHOSPHORYLATION; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOGENICITY; WESTERN BLOTTING;

BLOOD COAGULATION; BLOOD PLATELETS; BLOTTING, WESTERN; C-REACTIVE PROTEIN; CELL ADHESION MOLECULES; CYCLIC GMP; CYCLIC GMP-DEPENDENT PROTEIN KINASES; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; MICROFILAMENT PROTEINS; MICROSCOPY, CONFOCAL; PHOSPHOPROTEINS; PHOSPHORYLATION; PLATELET ADHESIVENESS; PLATELET AGGREGATION; PLATELET FUNCTION TESTS; PROTEIN MULTIMERIZATION; REGIONAL BLOOD FLOW; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP; THROMBOSIS; TIME FACTORS;

EID: 80054095828     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvr226     Document Type: Article

References (40)

1. Black S, Kushner I, Samols D. C-reactive protein. J Biol Chem 2004;279:48487-48490. (Pubitemid 39625721)
2. Jabs WJ, Theissing E, Nitschke M, Bechtel JF, Duchrow M, Mohamed S et al. Local generation of C-reactive protein in diseased coronary artery venous bypass grafts and normal vascular tissue. Circulation 2003;108:1428-1431. (Pubitemid 37176446)
3. Venugopal SK, Devaraj S, Jialal I. Macrophage conditioned medium induces the expression of C-reactive protein in human aortic endothelial cells: potential for paracrine/autocrine effects. Am J Pathol 2005;166:1265-1271. (Pubitemid 40524449)
4. Blake GJ, Ridker PM. C-reactive protein and other inflammatory risk markers in acute coronary syndromes. J Am Coll Cardiol 2003;41:37S-42S. (Pubitemid 36223345)
5. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002;347:1557-1565. (Pubitemid 35315836)
6. Jialal I, Devaraj S, Venugopal SK. C-reactive protein: risk marker or mediator in atherothrombosis? Hypertension 2004;44:6-11. (Pubitemid 38823477)
7. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest 2003;111: 1805-1812. (Pubitemid 38057722)
8. Elliott P, Chambers JC, Zhang W, Clarke R, Hopewell JC, Peden JF et al. Genetic loci associated with C-reactive protein levels and risk of coronary heart disease. JAMA 2009;302:37-48.
9. Kivimaki M, Lawlor DA, Smith GD, Kumari M, Donald A, Britton A et al. Does high C-reactive protein concentration increase atherosclerosis? The Whitehall II Study. PLoS One 2008;3:e3013.
10. Ji SR, Wu Y, Zhu L, Potempa LA, Sheng FL, LuWet al. Cell membranes and liposomes dissociate C-reactive protein (CRP) to form a new, biologically active structural intermediate: mCRP(m). FASEB J 2007;21:284-294. (Pubitemid 46052567)
11. Diehl EE, Haines GK III, Radosevich JA, Potempa LA. Immunohistochemical localization of modified C-reactive protein antigen in normal vascular tissue. Am J Med Sci 2000;319:79-83. (Pubitemid 30349650)
12. Kresl JJ, Potempa LA, Anderson BE. Conversion of native oligomeric to a modified monomeric form of human C-reactive protein. Int J Biochem Cell Biol 1998;30: 1415-1426. (Pubitemid 129750174)
13. Khreiss T, Jozsef L, Potempa LA, Filep JG. Opposing effects of C-reactive protein isoforms on shear-induced neutrophil-platelet adhesion and neutrophil aggregation in whole blood. Circulation 2004;110:2713-2720. (Pubitemid 39453024)
14. Khreiss T, Jozsef L, Potempa LA, Filep JG. Conformational rearrangement in C-reactive protein is required for proinflammatory actions on human endothelial cells. Circulation 2004;109:2016-2022. (Pubitemid 38544493)
15. Molins B, Pena E, Vilahur G, Mendieta C, Slevin M, Badimon L. C-reactive protein isoforms differ in their effects on thrombus growth. Arterioscler Thromb Vasc Biol 2008;28: 2239-2246.
16. Schwedler SB, Filep JG, Galle J, Wanner C, Potempa LA. C-reactive protein: a family of proteins to regulate cardiovascular function. Am J Kidney Dis 2006;47:212-222. (Pubitemid 43121324)
17. von Hundelshausen P, Weber C. Platelets as immune cells: bridging inflammation and cardiovascular disease. Circ Res 2007;100:27-40. (Pubitemid 46066771)
18. Vilahur G, Pena E, Padro T, Badimon L. Protein disulphide isomerase-mediated LA419-NO release provides additional antithrombotic effects to the blockade of the ADP receptor. Thromb Haemost 2007;97:650-657. (Pubitemid 46603437)
19. Llorente-Cortes V, Martinez-Gonzalez J, Badimon L. Esterified cholesterol accumulation induced by aggregated LDL uptake in human vascular smooth muscle cells is reduced by HMG-CoA reductase inhibitors. Arterioscler Thromb Vasc Biol 1998;18: 738-746. (Pubitemid 28267653)
20. Vilahur G, Hernandez-Vera R, Molins B, Casani L, Duran X, Padro T et al. Short-term myocardial ischemia induces cardiac modified C-reactive protein expression and proinflammatory gene (cyclo-oxygenase-2, monocyte chemoattractant protein-1, and tissue factor) upregulation in peripheral blood mononuclear cells. J Thromb Haemost 2009;7:485-493.
21. Molins B, Pena E, Padro T, Casani L, Mendieta C, Badimon L. Glucose-regulated protein 78 and platelet deposition: effect of rosuvastatin. Arterioscler Thromb Vasc Biol 2010;30:1246-1252.
22. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-2207.
23. Tennent GA, Hutchinson WL, Kahan MC, Hirschfield GM, Gallimore JR, Lewin J et al. Transgenic human CRP is not pro-atherogenic, pro-atherothrombotic or pro-inflammatory in apoE2/2 mice. Atherosclerosis 2008;196:248-255.
24. Teupser D, Weber O, Rao TN, Sass K, Thiery J, Fehling HJ. No reduction of atherosclerosis in C-reactive protein (CRP)-deficient mice. J Biol Chem 2011;286: 6272-6279.
25. Bisoendial RJ, Kastelein JJ, Levels JH, Zwaginga JJ, van den Bogaard B, Reitsma PH et al. Activation of inflammation and coagulation after infusion of C-reactive protein in humans. Circ Res 2005;96:714-716. (Pubitemid 40559509)
26. Halbrugge M, Friedrich C, Eigenthaler M, Schanzenbacher P,Walter U. Stoichiometric and reversible phosphorylation of a 46-kDa protein in human platelets in response to cGMP-and cAMP-elevating vasodilators. J Biol Chem 1990;265:3088-3093.
27. Harbeck B, Huttelmaier S, Schluter K, Jockusch BM, Illenberger S. Phosphorylation of the vasodilator-stimulated phosphoprotein regulates its interaction with actin. J Biol Chem 2000;275:30817-30825.
28. Schafer A, Wiesmann F, Neubauer S, Eigenthaler M, Bauersachs J, Channon KM. Rapid regulation of platelet activation in vivo by nitric oxide. Circulation 2004;109:1819-1822. (Pubitemid 38509113)
29. Taylor KE, Giddings JC, van den Berg CW. C-reactive protein-induced in vitro endothelial cell activation is an artefact caused by azide and lipopolysaccharide. Arterioscler Thromb Vasc Biol 2005;25:1225-1230. (Pubitemid 40776613)
30. van den Berg CW, Taylor KE, Lang D. C-reactive protein-induced in vitro vasorelaxation is an artefact caused by the presence of sodium azide in commercial preparations. Arterioscler Thromb Vasc Biol 2004;24:e168-e171.
31. Russo I, Del Mese P, Viretto M, Doronzo G, Mattiello L, Trovati M et al. Sodium azide, a bacteriostatic preservative contained in commercially available laboratory reagents, influences the responses of human platelets via the cGMP/PKG/VASP pathway. Clin Biochem 2008;41:343-349. (Pubitemid 351240900)
32. Heuertz RM, Schneider GP, Potempa LA, Webster RO. Native and modified C-reactive protein bind different receptors on human neutrophils. Int J Biochem Cell Biol 2005;37:320-335. (Pubitemid 39330193)
33. Boguslawski G, McGlynn PW, Potempa LA, Filep JG, Labarrere CA. Conduct unbecoming: C-reactive protein interactions with a broad range of protein molecules. J Heart Lung Transplant 2007;26:705-713. (Pubitemid 47001707)
34. Ji SR, Ma L, Bai CJ, Shi JM, Li HY, Potempa LA et al. Monomeric C-reactive protein activates endothelial cells via interaction with lipid raft microdomains. FASEB J 2009; 23:1806-1816.
35. Bodart V, Febbraio M, Demers A, McNicoll N, Pohankova P, Perreault A et al. CD36 mediates the cardiovascular action of growth hormone-releasing peptides in the heart. Circ Res 2002;90:844-849. (Pubitemid 34633875)
36. Febbraio M, Hajjar DP, Silverstein RL. CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. J Clin Invest 2001; 108:785-791. (Pubitemid 32880285)
37. Herczenik E, Bouma B, Korporaal SJ, Strangi R, Zeng Q, Gros P et al. Activation of human platelets by misfolded proteins. Arterioscler Thromb Vasc Biol 2007;27: 1657-1665. (Pubitemid 46986124)
38. Hoebe K, Georgel P, Rutschmann S, Du X, Mudd S, Crozat K et al. CD36 is a sensor of diacylglycerides. Nature 2005;433:523-527. (Pubitemid 40204309)
39. Krupinski J, Turu MM, Martinez-Gonzalez J, Carvajal A, Juan-Babot JO, Iborra E et al. Endogenous expression of C-reactive protein is increased in active (ulcerated noncomplicated) human carotid artery plaques. Stroke 2006;37:1200-1204. (Pubitemid 43731862)
40. Eisenhardt SU, Habersberger J, Murphy A, Chen YC, Woollard KJ, Bassler N et al. Dissociation of pentameric to monomeric C-reactive protein on activated platelets localizes inflammation to atherosclerotic plaques. Circ Res 2009;105:128-137.